Biogen Bounces Back With FDA Nod for High-Dose Spinal Muscular Atrophy Drug

Why It Matters

The high‑dose approval could stabilize Biogen’s declining SMA revenues and buy time for its pipeline, reinforcing the company’s growth trajectory in a competitive market.

Key Takeaways

• FDA greenlights two‑dose high‑dose Spinraza regimen.
• Loading phase cut from four to two injections.
• High‑dose aims to lift sales below $1.55 B.
• Data show significant motor improvement versus sham.
• Supports Biogen’s bridge to next‑gen salanersen.

Pulse Analysis

The spinal muscular atrophy (SMA) market has shifted dramatically since Spinraza’s 2016 launch. Once a $2.1 billion revenue driver, Biogen’s flagship antisense drug slipped to under $1.55 billion in 2025 as oral competitor Roche’s Evrysdi captured market share. The decline highlighted the vulnerability of a single‑product franchise in a therapeutic area where patients and payers increasingly favor convenience. Biogen’s response—securing a new high‑dose formulation—signals an attempt to reinvigorate the legacy brand while buying time for its next‑generation pipeline.

The FDA’s February 2026 approval trims the loading schedule from four 12‑mg doses to two 50‑mg injections spaced two weeks apart, followed by 28‑mg maintenance every four months. Phase 2/3 DEVOTE data demonstrated statistically significant motor‑skill gains over sham and a trend toward improvement versus the standard dose, all within a well‑characterized safety profile. For patients, the reduced injection burden translates into fewer hospital visits and lower procedural costs, potentially improving adherence. Clinicians also gain a more flexible dosing option that may extend therapeutic benefit for those who responded suboptimally to the original regimen.

From a commercial perspective, the high‑dose approval offers Biogen a short‑term revenue bridge while salanersen, its investigational antisense candidate, advances toward a possible 2028 readout. Analysts at Jefferies and BMO view the move as a “meaningful first step” to stabilize the SMA franchise and support the broader “bridge to growth” narrative that includes late‑stage pipeline launches and strategic acquisitions. If the new regimen sustains or modestly lifts sales, it could reassure investors and give Biogen leverage in negotiations for future partnerships or licensing deals.